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Background: We determined the association between Chronic liver disease and Gallstones in a representative sample of adults in Pakistan.
Methods: We included all the consecutive adults with HCV antibody positive and HBsAg positive, who visited our hepatology clinic from Jan 2009 to March 2009. We noted the status and duration of disease, weight, BMI, associated DM (Diabetes Mellitus), smoking, ethnicity and number of children in case of women.
Result: There were 344 participants, out of them 289 (84%) were HCV antibody positive and 55 (16%) were HBsAg positive. Overall prevalence of gallstones was 14.8%. 84.3% of gallstones were among HCV antibody positive and 15.7% among HBsAg positive individuals. Gallstones prevalence increased with age with a predominance in patients of more than 40 years of age (P value = 0.003). The frequency of gallstones increased with the duration of liver disease (P value = 0.05), peak was seen in patients who had chronic liver disease for 2 4 years. Conclusion: Chronic liver disease was strongly associated with gallstones among men but not in women in our study in Pakistan and gallstone was more common in adults with increasing age and severity of liver disease. Results: This study showed that the HCV core antigen and HCV RNA concentrations in 35 HCV patients were significantly related. Decrease of HCV core antigen and HCV RNA concentrations at 4th wk, 24th wk, 48th wk were observed during antiviral therapy. HCV core antigen at week 24 of therapy was significantly lower than at week 4 (P = 0.000). In contrast, no decrease was observed in HCV RNA concentrations in the same time (P = 0.303). HCV core antigen testing may be advantageous in some cases, especially the negativity of HCV core antigen at week 4 for prediction of non-response is reliable. Conclusion: HCV core antigen represents a stable and sensitive marker of viral replication, can be used to monitor the clinical efficacy of HCV antiviral therapy. Author contribution: Wen-Juan Wu and Yun-Zhi Zhang contributed equally to this work. Out of 35 patients who were checked for both HCV RNA and Anti-HCV 68.5% (n = 24) positive for both Anti-HCV and HCV RNA, while 31.5% were positive for anti-HCV but HCV RNA negative. These patients are believed to be immune to HCV. Conclusion: With the introduction of HCV quantification method as a diagnostic tool, it became possible to distinguish truly HCV immune patients who were considered as HCV infected before. We noticed positive correlation HCV viral load with liver enzymes. The method allows treatment monitoring for the first time in Mongolia.
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where HBV(1) HBcAb; disease limitation(1) long-standing of HCV-infection up to 5 years; disease limitation(2) 5 10 years. Probability of flu-like syndrome on first month of therapy is calculated by formula 2: Introduction: There is a growing evidence of intergenotypic recombination in HCV. In this paper we report a patient infected by HCV 1b and, probably, recombinant 2/1b that is detected in peripheral blood mononuclear cells (PBMC). Case description: Patient S., male, 31 years old admitted in January 2009. HCV viral load in serum before treatment 9,630,000 IU/ml. HCV genotyping by sequencing 5 UTR and NS5A. According to phylogenetic analysis NS5A belongs to 1b (sera and PMBC), 5 UTR from serum to 1b, from PBMC to genotype 2. Due to discordant results recombinant 2/1b in PBMC can be suspected. NS5A interferon sensitivity determining region (ISDR) contains mutation R2218H. Laboratory: ALT 71 U/l, AST 62 U/l, GGT 36 U/l. Liver biopsy: HAI 8, fibrosis 1. Immunohistochemically HCV NS3 was detected in lobules and tracts. Elevated CD16 and CD20 was found in lymphoid follicules of portal tracts. Patient received treatment with pegintron (1.5 mg/kg BW) plus ribavirin (1000 mg/day) for 48 weeks. Virological and biochemical response were achieved on 12 wk and remained until the end of treatment and during follow-up. Liver biopsy after treatment: HAI 3, fibrosis 0. Immunohistochemically NS3 was still detected in lobules and tracts, CD16 and CD20 decreased in portal tracts.
